Yahoo Finance1mon
EsoBiotec Doses First Patient in Investigator Initiated Trial of In Vivo BCMA CAR-T Candidate ESO-T01 for Multiple Myeloma
today announced the first patient has been dosed in an investigator-initiated clinical trial in China of ESO-T01 for relapsed/refractory multiple myeloma. ESO-T01 is an immune shielded lentiviral ...
Morningstar1mon
EsoBiotec Doses First Patient in Investigator Initiated Trial of In Vivo BCMA CAR-T Candidate ESO-T01 for Multiple Myeloma
ESO-T01 is the first in vivo BCMA CAR-T candidate to be dosed in a human clinical trial, and has been developed by EsoBiotec using its third-generation immune-shielded cell specific lentiviral ...